CFRX - ContraFect Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4894
+0.0031 (+0.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4863
Open0.5700
Bid0.3000 x 900
Ask0.4900 x 800
Day's Range0.4700 - 0.5700
52 Week Range0.3550 - 2.7200
Volume418,009
Avg. Volume726,148
Market Cap38.863M
Beta (3Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.13
Trade prices are not sourced from all markets
  • PR Newswire16 days ago

    X-Biotix Therapeutics Joins Antimicrobials Working Group

    WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...

  • PR Newswire27 days ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

    64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • Investors Who Bought ContraFect (NASDAQ:CFRX) Shares Three Years Ago Are Now Down 84%
    Simply Wall St.28 days ago

    Investors Who Bought ContraFect (NASDAQ:CFRX) Shares Three Years Ago Are Now Down 84%

    As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So spare a...

  • GlobeNewswirelast month

    ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data

    YONKERS, N.Y., June 17, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for.

  • PR Newswirelast month

    Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

    The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...

  • GlobeNewswirelast month

    ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that the Congressionally Directed Medical Research Programs (CDMRP) has awarded the Company $7.2 million in funding from the Military Infectious Diseases Research Program (MIDRP), United States Army Medical Research and Development Command (USAMRDC) over the course of three years to advance its lysin candidate, CF-296, through IND-enabling studies after which it may enter the clinic. CF-296 was discovered while the Company was working on its platform of direct lytic agents (DLAs). Lysins, a new class of DLAs, are antimicrobial biologics with a novel mechanism of action which results in the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics.

  • GlobeNewswirelast month

    ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development at ContraFect, will present at the invitation of the International Society of Cardiovascular Infectious Diseases (ISCVID) Symposium on Monday, June 3, 2019, in Lausanne, Switzerland. Dr. Cassino will discuss ContraFect’s lead phage-derived lysin candidate, exebacase, and promising data on the treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections, including endocarditis, from the Company’s Phase 2 clinical trial.

  • GlobeNewswire2 months ago

    ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that an article titled “Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus” will be published in the June edition of the peer-reviewed Antimicrobial Agents and Chemotherapy Journal of  the American Society of Microbiology. Exebacase (CF-301) is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of blood stream infections (BSIs) also known as bacteremia.

  • Zacks Small Cap Research2 months ago

    CFRX: R&D Symposium Highlights Positive Data for Exebacase…

    On May 14, 2019, ContraFect Corp. (CFRX) held an R&D symposium on the potential for direct lytic agents (lysins and amurins) as anti-infective agents. Included in the symposium were four presentations, including a discussion of the Phase 2 clinical trial of exebacase in patients with bacteremia caused by both methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant S. aureus (MRSA).

  • Associated Press2 months ago

    ContraFect: 1Q Earnings Snapshot

    The Yonkers, New York-based company said it had profit of 15 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update

    YONKERS, N.Y., May 10, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents,.

  • GlobeNewswire2 months ago

    ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that it will host an R&D Symposium with widely recognized infectious disease clinicians  on the broad potential of direct lytic agents as anti-infectives, with a focus on the methicillin-resistant Staphylococcus aureus (MRSA) data  from the Phase 2 trial of exebacase, on Tuesday, May 14, 2019, at 8:30 a.m. EDT in New York. A live webcast of the event will be available on the Investors & Media section of the Company’s website at www.contrafect.com.

  • Zacks Small Cap Research3 months ago

    CFRX: Additional Phase 2 Data Presented at ECCMID…

    The data was presented by Vance G. Fowler, Jr., M.D., Professor of Medicine in the Division of Infectious Diseases at Duke University. The Phase 2 trial was an international, multicenter, randomized, double blind, placebo controlled trial with a superiority comparison between exebacase or placebo combined with the standard of care antibiotics.

  • GlobeNewswire3 months ago

    ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    YONKERS, N.Y., April 16, 2019 (GLOBE NEWSWIRE) --  ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that new data from its Phase 2 clinical trial of exebacase for the treatment of Staphylococcus aureus (Staph aureus) bacteremia including endocarditis was presented by Vance G. Fowler, M.D., Professor of Medicine in the Division of Infectious Diseases, Duke University at a late-breaker session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The oral presentation, titled “Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics Alone In A First-in-Patient Phase 2 study,” reported new data demonstrating clinically meaningful increases in clinical responder rates in the pre-specified MRSA subgroup treated with exebacase, including a 22.9% higher responder rate at Day 7 and a 16.9% higher responder rate at Test of Cure, compared to MRSA patients treated with standard of care antibiotics (SOC) alone.

  • Benzinga3 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

    Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...

  • PR Newswire3 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...

  • GlobeNewswire3 months ago

    ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that its manuscript titled “The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis” was published in the April edition of the peer-reviewed Antimicrobial Agents and Chemotherapy Journal of the American Society of Microbiology. The manuscript highlights in vitro activity of exebacase (CF-301) in human blood versus in a conventional testing medium (cation-adjusted Mueller-Hinton broth (caMHB)), in which exebacase exhibited markedly higher potency (32 to ≥100-fold) in human blood versus caMHB in three standard microbiologic testing formats and demonstrated synergistic interaction with two key human blood factors.

  • GlobeNewswire3 months ago

    ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that Dr. Vance Fowler will present new data from the Phase 2 study of exebacase (CF-301) at a late-breaker session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 13-16, 2019, in Amsterdam, Netherlands. ContraFect will also deliver an oral presentation of novel data from its lysin program targeting resistant Gram-negative (GN) pathogens, which demonstrate the potential for lysins to re-sensitize carbapenem-resistant Pseudomonas aeruginosa (P. aeruginosa) to both meropenem and imipenem.

  • GlobeNewswire3 months ago

    ContraFect Announces CEO Transition

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that Roger J. Pomerantz, MD, FACP has been appointed Chairman and Chief Executive Officer of ContraFect and will succeed Steven C. Gilman, Ph.D., who is retiring from his position as Chairman and CEO.

  • GlobeNewswire4 months ago

    ContraFect to Present at the Bacteriophage Therapy Summit

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development will participate in the inaugural Bacteriophage Therapy Summit (“Summit”) to be held from March 25-27, 2019 in Boston, MA. Dr. Cassino was invited to the Summit to present ContraFect’s journey to positive results in its Phase 2 clinical study with the first non-traditional antibacterial to progress to this stage of development.

  • Zacks Small Cap Research4 months ago

    CFRX: Planning for Phase 3 Trial of Exebacase in S. Aureus Bacteremia…

    ContraFect Corp. (CFRX) is developing exebacase (CF-301), the company’s lead lysin product, for the treatment of bacteremia caused by Staphylococcus aureus infections. Exebacase has been tested in a number of pre-clinical studies and the company recently announced positive topline results from a Phase 2 study of exebacase (discussed below).

  • Associated Press4 months ago

    ContraFect: 4Q Earnings Snapshot

    On a per-share basis, the Yonkers, New York-based company said it had net income of 7 cents. Losses, adjusted for non-recurring gains, were 8 cents per share. The results exceeded Wall Street expectations. ...

  • GlobeNewswire4 months ago

    ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    YONKERS, N.Y., March 14, 2019 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated.

  • GlobeNewswire4 months ago

    ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of novel, differentiated biologic therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company's Chairman and Chief Executive Officer, will participate in the 29th Annual Oppenheimer Healthcare Conference on Wednesday, March 20, 2019, at 3:55 PM ET in New York City. The focus will be on exebacase (CF-301), the Company's novel therapeutic candidate for Staph aureus bacteremia, including endocarditis, along with an update on the progress of its other pipeline assets. A live webcast of the presentation will be available on the Investors & Media section of the Company’s website at www.contrafect.com.

  • GlobeNewswire4 months ago

    ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens

    ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the Company up to $6.94 million in non-dilutive funding to accelerate the development of its newly discovered and proprietary class of amurin peptides as potential therapeutics to treat serious and potentially life-threatening infections, including those caused by antibiotic-resistant Gram-negative ESKAPE pathogens. The company intends to progress these compounds as quickly as possible through hit-to-lead and optimization towards clinical development as potential treatments for pulmonary exacerbations of cystic fibrosis and hospital-acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP).